文献速递肾小球疾病遗传性与小管间质肾病

儿童Alport综合征无创诊断的尿液肽组学特征

Urinary Peptidomic Signature for Noninvasive Diagnosis of Alport Syndrome in Children.
PubMed 文献 · Kidney Int Rep · 2026-09-25

该研究基于毛细血管电泳-质谱分析尿液肽组,纳入57例AS患儿及651例儿科肾病与健康对照样本,随机分为发现集(70%)与验证集(30%),开发并验证支持向量机分类器。验证集中分类器AUC达0.999(95%CI 0.997-1.000),敏感度100%、特异度97.4%、准确率98.2%;校正年龄、性别和eGFR后AUC为0.918(95%CI 0.884-0.951),纵向分析显示评分稳定长达3年。

要点

  • 尿液肽组学分类器对儿童AS诊断验证集AUC为0.999,敏感度100%、特异度97.4%。
  • 校正年龄、性别和eGFR后AUC仍达0.918(95%CI 0.884-0.951)。
  • 分类器评分在长达3年的纵向分析中保持稳定。

核心结论

  • 开发并验证了一种准确的尿液肽组学分类器,可用于儿童Alport综合征的无创诊断。

研究设计与样本

  • 研究纳入EARLY PRO-TECT trial中57例AS患儿(80.7%为X连锁,平均年龄10±4岁,4%为女性,平均eGFR 128±31 ml/min per 1.73 m2)的282份尿样,以及651份来自儿科肾病队列和健康对照的样本。
  • 数据集随机分为发现集(70%)和验证集(30%),采用毛细管电泳-质谱分析尿液肽谱。
  • 通过Wilcoxon检验(Benjamini-Hochberg校正)识别差异肽,用于构建支持向量机分类器,并通过交叉验证和验证集评估性能。

主要发现

  • 共识别151个判别性肽,其中87个具有序列信息并用于分类器生成,60.9%为胶原来源。
  • 验证集中分类器AUC为0.999(95%CI 0.997-1.000),敏感度100%,特异度97.4%,准确率98.2%。
  • 校正年龄、性别和eGFR后,调整AUC为0.918(95%CI 0.884-0.951)。
  • 纵向分析显示分类器评分在长达3年内保持稳定。

临床怎么用

  • 该尿液肽组学特征可能作为基因检测的补充手段,支持儿童Alport综合征的早期识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Early diagnosis of Alport syndrome (AS) in children remains challenging because early manifestations are nonspecific. Some clinically suspected cases remain genetically unresolved because no disease-causing variant has been identified or the variants identified are of uncertain significance. Urinary peptidomics is a promising noninvasive biomarker approach. We aimed to develop and validate a urinary peptidomic signature for pediatric AS. METHODS: Urinary peptide profiles generated by capillary electrophoresis-mass spectrometry were analyzed in 282 urine samples from 57 children with AS (80.7% had X-linked disease, mean age was 10 ± 4 years, 4% were female, and mean estimated glomerular filtration rate [eGFR] was 128 ± 31 ml/min per 1.73 m2) enrolled in EARLY PRO-TECT trial, along with 651 samples from pediatric kidney disease cohorts and healthy controls. The data set was randomly divided into discovery (70%) and validation (30%) cohorts. Differential peptides identified by Wilcoxon testing with Benjamini-Hochberg adjustment were used to develop a support vector machine classifier. Performance was assessed by cross-validation and application to the validation cohort. RESULTS: A total of 151 discriminatory peptides were identified. Sequence information was available for 87 peptides used for classifier generation; 60.9% were collagen-derived. In validation, the classifier achieved an area under the receiver operating characteristic curve (AUC) of 0.999 (95% confidence interval [CI], 0.997-1.000), with 100% sensitivity, 97.4% specificity, and 98.2% accuracy. After adjustment for age, sex, and eGFR, performance remained high (adjusted AUC, 0.918 [95% CI, 0.884-0.951]). Longitudinal analyses demonstrated stable classifier scores over up to 3 years. CONCLUSION: We developed and validated an accurate urinary peptidomic classifier for noninvasive diagnosis of pediatric AS. The signature may complement genetic testing and support earlier recognition of AS.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Byrska J, Boeckhaus J, Voutsadaki K, et al. Urinary Peptidomic Signature for Noninvasive Diagnosis of Alport Syndrome in Children. Kidney Int Rep. 2026. PMID: 42927079. doi:10.1016/j.ekir.2026.107093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。